Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CLEARSIDE BIOMEDICAL, INC.

(CLSD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
6.51(c) 6.76(c) 6.9(c) 6.84(c) 6.4(c) Last
409 226 360 482 477 775 709 011 699 097 Volume
+2.52% +3.84% +2.07% -0.87% -6.43% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 21,2 M - -
Net income 2021 -7,72 M - -
Net cash position 2021 14,9 M - -
P/E ratio 2021 -45,7x
Yield 2021 -
Sales 2022 8,10 M - -
Net income 2022 -19,8 M - -
Net Debt 2022 18,8 M - -
P/E ratio 2022 -18,0x
Yield 2022 -
Capitalization 381 M 381 M -
EV / Sales 2021 17,3x
EV / Sales 2022 49,3x
Nbr of Employees 33
Free-Float 88,4%
More Financials
Company
Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Its proprietary suprachoroidal space (SCS) microinjector targeting SCS offers access to the macula, retina and choroid where sight-threatening disease often occurs. The SCS injection platform is an inherently... 
More about the company
Ratings of Clearside Biomedical, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CLEARSIDE BIOMEDICAL, INC.
09/21CLEARSIDE BIOMEDICAL : Says it Completed Dosing of Patients for Phase 1/2a Trial of Eye Tr..
MT
09/21CLEARSIDE BIOMEDICAL : Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical T..
AQ
09/21Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical ..
CI
09/20CLEARSIDE BIOMEDICAL, INC.(NASDAQGM : CLSD) added to S&P Global BMI Index
CI
09/09CLEARSIDE BIOMEDICAL : Expands Xipere License Deal With Arctic Vision
MT
09/09CLEARSIDE BIOMEDICAL : Expands XIPERE™ License Agreement with Arctic Vision to Inclu..
AQ
09/09Clearside Biomedical Expands XIPEREÖ License Agreement with Arctic Vision to Include Au..
CI
08/23Clearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Reti..
GL
08/16Arctic Vision Enters an Amendment to License Agreement with its Partner Clearside Biome..
CI
08/15ARCTIC VISION : Announces Expansion of License Territory for Suprachoroidal Space Injectio..
PR
08/10CLEARSIDE BIOMEDICAL : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/10CLEARSIDE BIOMEDICAL : Announces Second Quarter 2021 Financial Results and Provides Corpor..
PU
08/10CLEARSIDE BIOMEDICAL : CLS-AX OASIS Cohort 1 Clinical Data
PU
08/10CLEARSIDE BIOMEDICAL, INC. : Results of Operations and Financial Condition, Financial Stat..
AQ
08/10Clearside Biomedical, Inc. Reports Earnings Results for the Second Quarter Ended June 3..
CI
More news
News in other languages on CLEARSIDE BIOMEDICAL, INC.
09/09Clearside Biomedical étend le contrat de licence de Xipere avec Arctic Vision
More news
Analyst Recommendations on CLEARSIDE BIOMEDICAL, INC.
More recommendations
Chart CLEARSIDE BIOMEDICAL, INC.
Duration : Period :
Clearside Biomedical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLEARSIDE BIOMEDICAL, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 6,40 $
Average target price 11,60 $
Spread / Average Target 81,3%
EPS Revisions
Managers and Directors
George M. Lasezkay President, Chief Executive Officer & Director
Charles A. Deignan Chief Financial Officer
William D. Humphries Chairman
Rafael V. Andino Vice President-Engineering & Manufacturing
Thomas A. Ciulla Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
CLEARSIDE BIOMEDICAL, INC.133.58%407
GILEAD SCIENCES, INC.20.85%89 259
BIONTECH SE276.71%80 542
REGENERON PHARMACEUTICALS28.14%66 425
WUXI APPTEC CO., LTD.35.04%59 817
VERTEX PHARMACEUTICALS-22.40%47 634